Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05048537
Overview
Prostate cancer (PCa) is the fifth-most common cancer for male with a seventh highest cancer-related death in Taiwan. Currently, the incidence and mortality rate are still increasing rapidly. The treatment decision planning is made up by clinical charts like Gleason score (GS), TNM stage and serum prostate-specific antigen (PSA) level. However, after definitive therapy for PCa with either external beam radiotherapy (EBRT) or radical prostatectomy (RP), up to half patients experience biochemical recurrence (BCR). Although not all patients with BCR proceed to develop disease progression, it is important to identify early lesion to initiate salvage treatment.
Sponsor
National Taiwan University Hospital
Phase
N/A
Contacts
Yi-Hsien Chou, MD (Study Director)
y06922@ms1.ylh.gov.tw
+886-97252572
ClinicalTrials.gov
NCT05048537Drug / Compound
Help us improve your experience